Recent advances in the management of mucormycosis: from bench to bedside

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1743-1751

  Spellberg, Brad ^a,b,e   Walsh, Thomas J ^c   Kontoyiannis, Dimitrios P ^d   Edwards Jr , J John ^a,b   Ibrahim, Ashraf S ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CREATININE; DEFERASIROX; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VORICONAZOLE;

ACUTE KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; GRANULOCYTE TRANSFUSION; HUMAN; HYPERBARIC OXYGEN; IRON CHELATION; MONOTHERAPY; MUCORMYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BENZOIC ACIDS; CASE MANAGEMENT; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; IMMUNOLOGIC FACTORS; MUCORMYCOSIS; POLYENES; TRIAZOLES;

EID: 66949141526     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599105     Document Type: Review

References (96)

1. Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the fungi. Mycol Res 2007; 111:509-47.
2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53.
3. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18:556-69.
4. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004;45:1351-60.
5. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60.
6. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000;30:851-6.
7. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
8. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
9. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364-71.
10. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71.
11. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
12. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274-82.
13. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE Jr. Liposomal am- photericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003; 47:3343-4.
14. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate ofdissem- inated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49:830-2.
15. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63.
16. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49:4536-45.
17. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and phar- macokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24.
18. Benjamin DK, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in neonates [abstract A-012]. In: Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2008.
19. Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmaco- kinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632-8.
20. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008;52:1556-8.
21. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117:2649-57.
22. Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Anti- microb Agents Chemother 2008;52:1573-6.
23. Shoham S, Magill S, Merz WG, et al. Primary treatment of invasive zygomycosis in immunocompromised patients [abstract M-2174]. In: Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2008.
24. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2.
25. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39:425-9.
26. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-2.
27. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39:588-90.
28. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-6.
29. Ide L, Buysschaert I, Demuynck H, et al. Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole? Clin Microbiol Infect 2004; 10:862-3.
30. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40:e35-7.
31. Rickerts V, Bohme A, Just-Nubling G. Risk factor for invasive zygomycosis in patients with hematologic malignancies. Mycoses 2002; 45(Suppl 1):27-30.
32. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Anti- microb Agents Chemother 2003; 47:3647-50.
33. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003;51:45-52.
34. Van Cutsem J, Van Gerven F, Fransen J, Janssen PA. Treatment of experimental zygomycosis in guinea pigs with azoles and with am- photericin B. Chemotherapy 1989; 35:267-72.
35. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46:1032-7.
36. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90.
37. Lass-Florl C, Mayr A, Perkhofer S, et al. The activities of antifun- gal agents against yeasts and filamentous fungi: assessment according to EUCAST methodology. Antimicrob Agents Chemother 2008;52: 3637-41.
38. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and am- photericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008; 46:567-73.
39. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50:658-66.
40. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007; 51:812-8.
41. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36.
42. Walsh TJ, Raad I, Patterson TF, et al. Treatment ofinvasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
43. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Diekema DJ. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis 2003; 45:241-4.
44. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2008; 53:24-34.
45. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004;48:137-42.
46. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed- mouse model. Antimicrob Agents Chemother 2002; 46:2310-2.
47. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine- disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008; 52:3786-8.
48. Ibrahim AS, Gebermariam T, Schwartz JA, Edwards JE Jr, Spellberg B. Posaconazole mono- or combination therapy for the treatment ofmu- rine zygomycosis. Antimicrob Agents Chemother 2009; 53:772-5.
49. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-5.
50. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50:126-33.
51. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005;49:721-7.
52. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198:186-92.
53. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994;45: 667-71.
54. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest 1993; 91:1979-86.
55. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994;47:1843-50.
56. Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006;58:1070-3.
57. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005; 18:289-98.
58. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91:873-80.
59. Miyazawa K, Ohyashiki K, Urabe A, et al. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a phase I study in Japan. Int J Hematol 2008; 88:73-81.
60. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucor- mycosis. Antimicrob Agents Chemother 2006; 50:3968-9.
61. Soummer A, Mathonnet A, Scatton O, et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother 2008; 52:1585-6.
62. Sechaud R, Robeva A, Belleli R, Balez S. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol 2008;48:919-25.
63. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008; 83:398-402.
64. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002;509:185-203.
65. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood 2006; 107:3455-62.
66. Important information about exjade (deferasirox) tablets for oral suspension. Novartis, 2007. Available at: http://www.fda.gov/MEDwatch/ safety/2007/Exjade-DHCPL-May2007.pdf. Accessed 22 April 2009.
67. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-g and granulocyte-macrophage colony- stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005; 191:1180-7.
68. Abzug MJ, Walsh TJ. Interferon-γ and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004; 23:769-73.
69. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997;24:192-6.
70. Kullberg BJ, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. Res Immunol 1998; 149:478-88; discussion 515.
71. Ma B, Seymour JF, Januszewicz H, Slavin MA. Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk Lymphoma 2001;42: 1393-9.
72. Mastroianni A. Paranasal sinus mucormycosis in an immunocompe- tent host: efficacy and safety of combination therapy with liposomal amphotericin B and adjuvant rHuGM-CSF. Infez Med 2004; 12:278-83.
73. Grigull L, Beilken A, Schmid H, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and GCSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer 2006; 14:783-6.
74. Slavin MA, Kannan K, Buchanan MR, Sasadeusz J, Roberts AW. Successful allogeneic stem cell transplant after invasive pulmonary zygo- mycosis. Leuk Lymphoma 2002; 43:437-9.
75. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005; 11: 515-7.
76. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47:503-9.
77. Kontoyiannis DP, Chamilos G, Hassan SA, Lewis RE, Albert ND, Tar- rand JJ. Increased culture recovery of zygomycetes under physiologic temperature conditions. Am J Clin Pathol 2007; 127:208-12.
78. Francesconi A, Kasai M, Harrington SM, et al. Automated and manual methods of DNA extraction for Aspergillus fumigatus and Rhizopus oryzae analyzed by quantitative real-time PCR. J Clin Microbiol 2008; 46:1978-84.
79. Hata DJ, Buckwalter SP, Pritt BS, Roberts GD, Wengenack NL. Real-time PCR method for detection of zygomycetes. J Clin Microbiol 2008; 46:2353-8.
80. Kasai M, Harrington SM, Francesconi A, et al. Detection ofa molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 2008; 46:3690-702.
81. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary as- pergillosis in patients with cancer. Clin Infect Dis 2005; 41:60-6.
82. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008; 46:1733-7.
83. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D'Souza O. Rhino-orbito-cerebral mucormycosis: a retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003;51:231-6.
84. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mu- cormycosis: evolution of the disease and treatment options. Laryngoscope 1997; 107:855-62.
85. Khor BS, Lee MH, Leu HS, Liu JW. Rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect 2003; 36:266-9.
86. Petrikkos G, Skiada A, Sambatakou H, et al. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003; 22:753-6.
87. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results ofmedical and surgical therapy. Ann Thorac Surg 1994;57:1044-50.
88. Pavie J, Lafaurie M, Lacroix C, et al. Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy. Scand J Infect Dis 2004;36: 767-9.
89. Reid VJ, Solnik DL, Daskalakis T, Sheka KP. Management of bronchovascular mucormycosis in a diabetic: a surgical success. Ann Thorac Surg 2004;78:1449-51.
90. Asai K, Suzuki K, Takahashi T, Ito Y, Kazui T, Kita Y. Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg 2003; 51:163-6.
91. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487-96.
92. Walsh TJ, Kontoyiannis DP. Editorial commentary: what is the role of combination therapy in management of zygomycosis? Clin Infect Dis 2008; 47:372-4.
93. Spellberg BJ, Gebremariam T, Edwards JE, Ibrahim AS. Posaconazole mono- or combination therapy for murine mucormycosis [abstract M3762]. In: Program and abstracts of the Interscience Convention on Antimicrobial Agents and Chemotherapy(ICAAC)-Infectious Diseases Society of America (IDSA). Washington, DC: IDSA, 2008.
94. Novartis. Exjade patient assistance and support services. Available at: http://www.us.exjade.com/info/getting-exjade/home.jsp. Accessed 11 May 2009.
95. Simitsopoulou M, Roilides E, Maloukou A, Gil-Lamaignere C, Walsh TJ. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against zygomycetes. Mycoses 2008;51:147-54.
96. Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998;26:601-5.